

410 Rec'd PCT/PTO 26 SEP 2000
09/647098

LAW OFFICES
SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, DC 20037-3213
TELEPHONE (202) 293-7060
FACSIMILE (202) 293-7860

September 26, 2000

Assistant Commissioner
of Patents
Washington, D.C. 20231

ATTN: BOX PCT
PCT/AU99/00232
Attorney Docket: Q-60901

Re: Application of David Grant RICHARDS, Wayne Keith JORGENSEN and Norman Porter STEWART for
"VACCINATION MODALITIES"

Sir:

Please enter the enclosed above identified application into the national stage commencement under Chapter II along with the claim to priority and Preliminary Amendment. It is assumed that copies of the Int'l Application, Int'l Search Report, International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the Int'l Bureau, but if copies are needed, please notify the undersigned.

The Government filing fee is calculated as follows:

Total claims 10 - 20 = 00 x \$18/09 = \$
Independent Claims 01 - 03 = 00 x \$78/39 = \$
Basic Fee (970/485) or (840/420) = \$ 840.00
Multiple Dependent Claim Fee = \$
Assignment Recordal Fee = \$
TOTAL FILING FEE \$ 840.00

Attached please find a check in the amount of \$ 840. for the basic filing fee. You are directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880.

Priority is claimed from Australian Application No. PP 2683 filed March 30, 1998. The International Application PCT/AU99/00232 was filed March 30, 1999. The executed Declaration and Assignment documents will be submitted in due course.

A duplicate copy of this transmittal letter is attached.

Respectfully submitted,

Bruce E. Kramer
Bruce E. Kramer
Reg. No. 33,725 for
Robert V. Sloan
Reg. No. 22,775

RVS:jljg
Attachments:

09/647098

529 Rec'd PCT/PTO 26 SEP 2000

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the PCT Application of

David G. RICHARDS et al.

based on Int'l. Appl. No. PCT/AU99/00232

filed March 30, 1999

Filed: September 26, 2000

For: VACCINATION MODALITIES

Ass't Commissioner of Patents
Washington, DC 20231

ATTENTION: BOX PCT

Sir:

PRELIMINARY AMENDMENT

Prior to the calculation of filing fees and prior to initial examination, please amend the above identified PCT application as follows:

IN THE CLAIMS:

Claim 9, line 1, change "12" to -- 1 --.

REMARKS

Claim 9 has been amended to correct a typographical error.

PATENT APPLICATION

An early and favorable action on the merits is respectfully
requested.

Respectfully submitted,

Bruce E. Kramer

Bruce E. Kramer
Reg. No. 33,725
Robert V. Sloan
Reg. No. 22,775

RVS:jlq

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
(202) 293-7060

Fax: (202) 293-7860

Date: September 26, 2000

Att'y Docket No: Q-60901

09/647098

- 1 -

529 Rec'd PCT/PTO 26 SEP 2000

VACCINATION MODALITIES

This invention relates to vaccination strains of *Eimeria* and vaccines including the same.

- 5 Coccidiosis is a disease of major economic importance for the intensive poultry industry conducted around the world. The causative agent is *Eimeria*, a protozoan parasite.

In the chicken seven different species of *Eimeria* have been identified, namely *E. maxima*, *E. acervulina*, *E. necatrix*, *E. tenella*, *E. mitis*, *E. praecox* and *E. brunetti*. Not all of these
10 species may be present in any particular country or region. *E. maxima*, *E. acervulina*, *E. necatrix* and *E. tenella* are prevalent species of *Eimeria*.

Eimeria have a complicated life cycle, details of which are well described, for example, in *Poultry Coccidiosis: Diagnostic and testing procedures*, Second Edition, Pfizer Inc. Briefly,
15 when a sporulated (infective) coccidial oocyst is ingested, sporozoites are released to initiate asexual and sexual cycles that lead to the development of thousands of new oocysts, which are shed in the faeces. These oocysts sporulate shortly thereafter and then are infectious for other birds. A single sporulated oocyst may give rise to as many as ten thousand progeny. *Eimeria* produce lesions in the gut by destruction of the epithelial cells in which they develop
20 and multiply, and by trauma to the intestinal mucosa and submucosa.

The various species of *Eimeria* (which may otherwise be referred to as coccidia) can be identified by microscopic features of oocysts (size, shape, length and width), the preferred locations of coccidia in the gut, the nature of the lesions produced, prepatent period,
25 sporulation times and reproductive index, DNA testing and lack of cross protection between species. Identification of a particular species' infection can therefore be made with general accuracy based on any one or more of these features.

The clinical signs of coccidiosis include diarrhoea, which may be mucoid or bloody and
30 dehydration. These symptoms are generally followed by ruffled feathers, anaemia,

- 2 -

listlessness, loss of weight, retraction of the head and neck and somnolence. Coccidiosis in laying hens is usually observed by a drop in egg production. Infected growing birds, soon cease to grow satisfactorily. With highly virulent strains mortality in chickens is generally very high.

5

According to 1997 figures about twenty billion birds are reared each year across the world. Control of coccidiosis in such a large bird population has generally been by anti-coccidial drugs which have in the whole been effective. Not surprisingly, however, drug resistance is now a problem with an increasing number of *Eimeria* strains being resistant to
10 chemotherapeutic drugs. The development of drug resistant, highly virulent *Eimeria* strains has the potential to devastate the poultry industry.

The possible control of coccidiosis by vaccination has received interest over the years, without any great success. Attempts to develop genetically engineered or sub-unit vaccines
15 have so far been unsuccessful (Shirley, 1992, *Br. Vet. J.*, 148:479). A living vaccine, (Paracox, Pitman-Moore) containing oocysts from attenuated strains of coccidia has been used in Great Britain (Farrent, 1992, *Poultry World*, 4:11).

The Paracox live vaccine referred to above is based on precocious lines of various *Eimeria*
20 species. Precocious lines of *Eimeria* are populations that complete their endogenous life cycle in the host more quickly than wild-type strains. The process of this selection was first described by Jeffers (1975, *J. Parasitol.* 61, 1083-1090). Serial passage in the chicken of the first oocyst produced during infection yields parasites characterised by an abbreviated life cycle, and possibly some attenuation of virulence. Problems associated with precocious lines
25 are failure to protect against virulent *Eimeria* species, poor reproductive capacity such that it is not feasible to produce a vaccine using such strains, and issues of stability associated with attenuation, and maintenance of infectivity. For example, Shirley and Bellatti (1988, *Re. Vet. Sci.*, 44:25-28) describe a precocious line of *E. maxima* which protected poorly against challenge with virulent heterologous strains.

30

- 3 -

The present inventors have surprisingly produced vaccine strains of *E. maxima*, *E. acervulina*, *E. tenella* and *E. necatrix*, which are strongly protective against virulent strains from their respective species, grow at a rate which allow vaccine production, and are stable

- 5 The geographical isolation of Australia from foreign coccidial diseases ensures the vaccines and vaccine strains described herein are unique, and therefore clearly distinguishable from previously described precocious *Eimeria* strains.

- In accordance with a first aspect of this invention, there is provided a vaccine which includes
- 10 one or more strains of *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* MCK01 and/or *E. necatrix* ARI-MEDNEC₃+8, or antigens of said one or more strains, in association with a veterinarily acceptable carrier or excipient.

- The vaccine may contain other *Eimeria* species in addition to the strains referred to above.
- 15 For example such additional species may be *Eimeria* strains of *E. brunetti*, *E. mitis*, and/or *E. praecox* and/or one or more other vaccine strains of *E. maxima*, *E. acervulina*, *E. necatrix* and/or *E. tenella*. Such additional strains, may not be as useful as the strains of the present invention, however they may still be advantageous components of a wide spectrum vaccine composition. The vaccine may also include at least one additional unattenuate strain. For
- 20 example, one embodiment of a vaccine may contain *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98 and/or *E. necatrix* MCK01, and/or *E. necatrix* ARI-MEDNEC₃+8, and optionally one or more strains selected from *E. brunetti*, *E. mitis*, *E. mivati*, and/or *E. praecox* to give a multivalent vaccine. A preferred vaccine contains three to five vaccine strains of *Eimeria* selected from *E. maxima* ARI-73/97, *E. acervulina* ARI-
- 25 77/97, *E. tenella* ARI-11/98 and/or *E. necatrix* MCK01, and/or *E. necatrix* ARI-MEDNEC₃+8.

- Additional strains of this invention having vaccine competency may be prepared by immunising birds with one or more of the strains *E. maxima* ARI-73/97, *E. acervulina* ARI-
- 30 77/97, *E. tenella* ARI-11/98 and/or *E. necatrix* MCK01, and challenging the immunised birds

- 4 -

with candidate strains from field isolates. Those strains which produce a large number of oocysts in the immunised birds, due to the vaccine not being cross protective for them (an unlikely event), are then subject to serial passage through birds to give a strain of the invention being strongly protective against virulent strains, having a reproductive rate which
5 allows vaccine production, is stable, and sensitive to coccidiostatic drugs.

The organisms in the vaccines of this invention are in the form of whole and/or fractured or sporulated oocysts or sporocysts, or antigens thereof capable of inducing a protective immune response in a vaccinated bird. For convenience the term oocysts will be taken to mean
10 sporulated oocysts, or a mixture of oocysts and sporulated oocysts. Oocysts are sporulated according to methods well known in the art, such as described by Jensen et al (1976) *The Journal of Parasitology* 2, 195-198, and 199-202. Sporulated oocysts or sporocysts are infective to birds by the oral, eye drop, nasal, or parenteral route. Antigens are generally proteins or peptides or fragments thereof (comprising for example 5 or more amino acids,
15 such as from 5 to 50 amino acids). Carbohydrates, lipids, glycolipids and the like may also comprise antigens. Antigens are generally derived from the sporozoite stage of the organisms. Antigens may be produced by standard means including recombinant DNA technology, protein purification and other techniques as are well known in the art.

20 Veterinarily acceptable carriers include water, saline, buffered saline such as phosphate buffered saline, or any other physiologically suitable medium. Carriers may include one or more suspending agents, thickening agents or preservatives including physiologically suitable gels, gelatins, hydrosols, cellulose or polysaccharide gums. Excipients may include vitamins, antibiotics and antifungals (virucides, bacteriocides and/or fungicides), surfactants and the
25 like. Examples include one or more of streptomycin, linomycin, amphotericin, formaldehyde, chicken bile, sodium hypochlorite, sodium taurocholate, foetal calf serum and cystine hydrochloride.

Vaccines may comprise one or more *Eimeria* strains, and may contain from about 50 to about
30 50,000 sporulated oocysts per ml or more. The number of each *Eimeria* species present in

- 5 -

the vaccine will generally be the same for the strains according to this invention. However, where additional vaccine strains are used, for example such as from *E. brunetti*, which are additional strains and not strains according to the present invention, a larger number of organisms may be proportionally used due to the less protective response compared with the strains of this invention. By way of example vaccines, such as for ocular or oral administration, a vaccine dose may comprise 15 to 500 sporulated oocysts.

The vaccines according to this invention may contain other vaccine components effective against other poultry disease. Examples include Marek's vaccine, Fowl Pox, Mycoplasma and Salmonella vaccines. Hence in another aspect of this invention there is provided a vaccine as hereinbefore described which includes vaccine components against one or more of Marek's disease, mycoplasma or Salmonella infection.

The vaccines according to this invention may be administered *in ovo* (for example from days 18-20 of incubation), to chicks and adult birds. The route of administration may be orally, intraocularly through the lacrimal ducts, or by other known means of vaccine administration. As an example, a vaccine in an appropriate medium may be sprayed over a group of birds, sprayed on feed, administered as an eye drop, in feed water, as a part of prepared feed, or incorporated into a peck gel (such as sporulated oocysts in a gelatin matrix).

In another aspect this invention relates to vaccine *Eimeria* strains selected from the group *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* MCK01, and/or *E. necatrix* ARI-MEDNEC₃+8. Preferably the strains are provided in the form of oocysts and/or sporulated oocysts.

Deposits of the *Eimeria* strains according to this invention were made with the Australian Government Analytical Laboratories (AGAL) a Budapest Treaty Depository, of 1 Suakin Street, Pymble, New South Wales, 2073, Australia on 17 March 1998, with the exception of *E. necatrix* ARI-MEDNEC₃+8 which was deposited on 30 March 1999. Details are as follows:

- 6 -

	Strain	Accession No.
	<i>E. maxima</i> ARI 73/97	NM 98/02796
	<i>E. acervulina</i> ARI-77/97	NM 98/02794
5	<i>E. necatrix</i> MCK01	NM 98/02797
	<i>E. necatrix</i> ARI-MEDNEC ₃ +8	NM 99/02118
	<i>E. tenella</i> ARI-11/98	NM 98/02795

10 The *Eimeria* strains of the present invention may be reproduced by standard procedures in the art, such as the passage through naive uninfected fowl (i.e. not subject to *Eimeria* infection). Each strain may be produced in an uninfected fowl, oocysts recovered, optionally sporulated and then combined with a carrier and/or excipient. *Eimeria* strains may be grown in eggs according to standard procedures and oocysts recovered from the eggs. *Eimeria* strains can be routinely adapted to growth and reproduction in eggs by conventional means.

15 Oocysts and/or sporocysts of *Eimeria* strains according to the invention may be frozen (cryopreserved) in liquid nitrogen for storage according to methods known in the art such as according to M.W. Shirley, *Biotechnology Guidelines on Techniques in Coccidiosis Research* pp 97- (1995) ISBN 92-827-4970-3. By way of example sporocysts suspended in protein
20 enriched media may be frozen in liquid nitrogen in the presence of dimethyl sulfoxide or glycerol, such as from 1 to 10% w/w.

This invention will now be described with reference to the following non-limiting examples:

25 EXAMPLE 1

A large number of *Eimeria* isolates from non-commercial (backyard) chicken flocks in Queensland of varying pathogenicity were collected. The isolates were generally mixed populations of *Eimeria* species however in most cases a single *Eimeria* species was the
30 predominant pathogenic organism. Isolates were sorted by microscopic analysis into their

- 7 -

respective species selected from *E. maxima*, *E. acervulina*, *E. tenella* and/or *E. necatrix*. Single oocysts from strains of each species were used to infect individual non-*Eimeria* infected birds generally in a volume of media, such as about 1ml. Faeces from these birds were monitored for oocysts using the salt flotation technique (M.W. Shirley, *Biotechnology* 5 *Guidelines on Techniques in Coccidiosis Research* pp 1-25 (1995) ISBN 92-827-4970-3) and oocysts recovered.

Individual *Eimeria* free birds were infected with up to 2000 oocysts of the purified strains to amplify them. These birds were euthanased and examined to confirm that the intestinal 10 lesions were consistent with the species with which the bird was infected using the criteria mentioned above.

Attenuating the strains

15 Strains were attenuated by serial passage by selecting for rapid development. Briefly, birds were infected with 1000-5000 parasites and monitored so that the first parasites voided were collected separately. This process was repeated a number of times (such as from 5 to 30 times) and parasites were progressively selected that developed faster; coinciding with this was their diminished ability to multiply in the chicken's gut and cause lesions. For many 20 isolates precocious strains could not be produced, the strains were extremely pathogenic, showed poor growth rates, were drug resistant, and/or were unstable. These strains were discarded. On testing of the remaining strains for protection against challenge with a heterologous strain from the same species, many strains failed to provide cross protection within *Eimeria* species which is essential for vaccine development. From this work four 25 vaccine strains of *Eimeria* were surprisingly produced from the species *E. maxima*, *E. acervulina*, *E. tenella* and *E. necatrix* all of which are strongly protective against virulent strains from their respective species, grow at a rate which allow vaccine production, were non-resistant to coccidiostatic drugs and are stable. The strains were designated *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* ARI-MEDNEC₃+8 30 and *E. necatrix* MCK01.

- 8 -

Oocysts were sporulated as follows: Faeces containing oocysts are placed into a solution of potassium dichromate. The dichromate acts as a bacteriostat. Air is bubbled through the solution. The process takes place in an incubator at 30°C. The process of sporulation is verified by observing the changes in the oocysts under a light microscope at a minimum of 100 x magnification. Sporulation time is between 18 to 30 hours, depending on the species. After sporulation suspensions are placed into a refrigerator for vaccine preparation or storage.

Where there is less than 100 ml of faeces and dichromate, 50 ml of faecal suspension is placed into large Petrie dishes and placed into the incubator at 30°C. There is sufficient surface area and minimum depth to ensure oxygen diffuses into the mixture and sporulation occurs.

Strains were cryopreserved such as by immersion of oocysts in media (in an appropriate receptacle) into liquid nitrogen.

EXAMPLE 2

A series of trials were carried out using vaccines containing each of the strains produced in Example 1, combinations of from 2 to 4 of these strains, as well as various combinations of strains according to Example 1 combined with other strains to give a vaccine. All these vaccines showed excellent protection against infection with heterologous *Eimeria* strains as well as treatment of *Eimeria* infection.

In one experiment sporocysts of *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97 were combined in a vaccine with the Medichick strain of *E. necatrix*, and the Darryl strain of *E. tenella*. Birds were vaccinated with a vaccine containing 250 sporulated oocysts of each strain combined in 1 ml of saline.

Birds were maintained on solid floors within the wire cages for 21 days to assist reinfection with excreted oocysts. Feed and water were provided *ad lib* throughout the trial.

All birds were individually weighed and marked by wing clipping at time of challenge. Vaccinated and susceptible positive control groups of birds were either challenged with 6000 heterologous strain sporulated oocysts of Ingham's *Eimeria* strains of *E. tenella* and *E. necatrix*, and Medichick strains (*E. maxima* and *E. acervulina*) or 6000 oocysts of 5 homologous strains. Weight gains and morbidity were compared between infected birds of the different treatment groups and uninfected control groups after 12 days. Results are shown in Table 1. ANOVA models (analysis of variance) appropriate to the designs were used to test the effects of treatments for statistical significance.

10 Table 1

Pen trial to compare mean live weight¹ gain in birds vaccinated as above and susceptible birds when challenged with 6×10^3 oocysts each of Medichick strains of *E. acervulina* and *E. maxima* and Ingham's strains of *E. tenella* and *E. necatrix* or 6×10^3 oocysts each of 15 homologous strains of the 4 parasites.

Treatment group (6 replicates)	Vaccination dose Quadravalent	Challenge dose ²	Number of birds euthanased during challenge due to clinical symptoms	Mean weight gain (grams per bird) ³
1	25 oocysts of each of the 4 species	6×10^3 oocysts of each heterologous strain	0/18	148 ^b
2	25 oocysts of each of the 4 species	6×10^3 oocysts of each homologous strain	0/18	227 ^a
3	nil	6×10^3 oocysts of each heterologous strain	4/18	28 ^d

- 10 -

Treatment group (6 replicates)	Vaccination dose Quadivalent	Challenge dose ²	Number of birds euthanased during challenge due to clinical symptoms	Mean weight gain (grams per bird) ³
4	nil	6 x 10 ³ oocysts of each homologous strain	3/18	78 ^c
5	nil	nil	0/18	201 ^a
LSD (P=0.05)	-	-	-	36

5 ¹ measured 12 days after challenge

² given on day 21 post vaccination

³ Means within columns followed by common superscript letters are not significantly different at the 5% level.

10 As shown in Table 1 all vaccinated groups had significantly greater weight gains upon challenge with heterologous or homologous strains than unvaccinated birds. Clinical symptoms of *Eimeria* infection were not observed in the vaccinated birds, compared with the untreated birds.

15 EXAMPLE 3

A vaccine comprising *E. maxima* ARI-73/97 (15 oocysts), *E. acervulina* ARI-77/97 (25 oocysts), *E. tenella* ARI-11/98 (25 oocysts) and *E. necatrix* MCK01 (15 oocysts) per vaccine dose was prepared. The vaccine was used in a trial to measure body weight and immune stimulation of birds subject to immunisation, compared with control non-vaccinated birds. Of the four groups of birds tested, the first received the vaccine by eye drop, the second orally by feed, the third orally by drinking water, and the fourth group was a control. Birds were maintained in pens with solid floors and were reared on feed and water *ad libitum*, with light and heating being provided by lamps.

- 11 -

Post vaccination, all groups of birds vaccinated at one day old or at six days had similar growth rates when compared with unvaccinated controls. This indicates the vaccine does not effect growth rate underscoring its utility. Birds were challenged with *Eimeria* strains at 10 x the number of oocysts used for vaccination.

5

Unvaccinated and challenged birds had a significantly higher oocyst production, which is characteristic for the spread of *Eimeria* infection amongst birds. The markedly reduced number of oocysts produced by vaccinated birds demonstrates a protective immunising response.

10

The unvaccinated group showed a growth rate drop post challenge whereas vaccinated birds continued to gain body weight. This is again a demonstration of a protective immunising response.

15 **EXAMPLE 4**

Vaccine compositions comprising sporulated oocysts of the aforementioned strains are prepared by suspension of sporulated oocysts in DulbeccoA phosphate buffered saline (Oxoid Laboratories, Heidelberg, Melbourne, Australia) at pH 7.4, containing 0.1 % formaldehyde.

20 Equal numbers of sporulated oocysts for each of strains *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, and *E. necatrix* ARI-MEDNEC3+8, and/or *E. necatrix* MCK01 are used.

A vaccine for oral administration comprises 500 doses per ml comprising 90 oocysts per
25 dose.

A vaccine for ocular administration comprises 40 doses per ml comprising 108 oocysts per dose.

- 12 -

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising" or the term "includes" or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claims is to be regarded as within the scope of the invention given that the essential features of the invention as claimed are included in such an embodiment.

10

"064799" 05004
"064799" 05004

THE CLAIMS

1. A vaccine which includes one or more strains of *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* MCK01 and/or *E. necatrix* ARI-MEDNEC₃+8, or antigens of said one or more strains, in association with a
5 veterinarianially acceptable carrier or excipient.
2. A vaccine according to claim 1 which includes at least one additional unattenuate *Eimeria* strain.
- 10 3. A vaccine according to claim 1 which includes *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, and one or both of *E. necatrix* MCK01 and *E. necatrix* ARI-MEDNEC₃+8.
- 15 4. A vaccine according to claim 3 which includes vaccine strains of *E. brunetti*, *E. mitis* and *E. praecox*.
5. A vaccine according to claim 1 which includes a vaccine against another poultry disease.
- 20 6. A vaccine according to claim 5 which includes vaccine components effective against one or more of Marek's disease, mycoplasma or salmonella infection.
7. An *Eimeria* strain selected from *E. maxima* ARI-73/97, *E. acervulina* ARI-77/97, *E. tenella* ARI-11/98, *E. necatrix* MCK01 and/or *E. necatrix* ARI-MEDNEC₃+8, or antigens
25 of said one or more strains.
8. A vaccine according to claim 1 wherein said strains are in the form of whole and/or factured sporulated oocysts or sporocysts.

**STATEMENT BY JOINT INVENTORS ON BEHALF
OF NONSIGNING INVENTOR WHO REFUSES TO SIGN**

We, joint inventors of U.S. Patent Application Serial No. 09/647,098, filed September 26, 2000, entitled "Vaccination Modalities", have signed the attached Declaration and Power of Attorney on our own behalf, and also sign the attached Declaration and Power of Attorney under 37 C.F.R. § 1.47(a) on behalf of the nonsigning joint inventor Norman Porter Stewart, who refuses to sign.

The County of citizenship of Mr. Stewart is Australian, and his last known address is 25 Ocean View Street, Point Vernon, Harvey Bay, Queensland 4655, AUSTRALIA.

30 Apr 2001
Date

30 / 4 / 2001
Date

David Grant Richards
David Grant Richards

Wayne Keith Jorgensen
Wayne Keith Jorgensen

09647098.050201

SOLE/JOINT

DECLARATION AND POWER OF ATTORNEY

Q-60901

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name: that I verily believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

VACCINATION MODALITIES

which application is:

☐ the attached application
(for original application)

☒ application Serial No. PCT/AU/99/00232
filed 30 March, 1999, and amended on _____

(for declaration not accompanying application)

that I have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware which is material to the patentability of this application under 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any provisional application or foreign application(s) for patent or inventor's certificate listed below and have also identified on said list any foreign application for patent or inventor's certificate on this invention having a filing date before that of any foreign application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed (yes or no)
PP 2683	Australia	30 Mar. 1998	YES

I hereby claim the benefit of Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application under 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (patented, pending, abandoned)

I hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon L. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603 and George F. Lehnigk, Reg. No. 36,359 my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 04 Dec 2000 First Inventor David Grant RICHARDS
First Name Middle Initial Last Name
Residence Victoria Signature [Signature]
Australia Post Office Address 29 Tantani Street, Frankston North, Victoria
Citizenship Australian 3200, AUSTRALIA

2w
Date 22/12/00 Second Inventor Wayne Keith JORGENSEN

Residence Queensland, AUSTRALIA AKX Signature W. Jorgensen

Post Office Address: 9 St Amand Street, Sinnamon Park, Brisbane, Queensland 4073, AUSTRALIA

Citizenship Australian

300
Date _____ Third Inventor Norman Porter STEWART

Residence Queensland, AUSTRALIA AKX Signature _____

Post Office Address: 25 Ocean View Street, Point Vernon, Harvey Bay, Queensland 4655, AUSTRALIA

Citizenship Australian

Date _____ Fourth Inventor _____

Residence _____ Signature _____

Post Office Address: _____

Citizenship _____

Date _____ Fifth Inventor _____

Residence _____ Signature _____

Post Office Address: _____

Citizenship _____

Date _____ Sixth Inventor _____

Residence _____ Signature _____

Post Office Address: _____

Citizenship _____

Date _____ Seventh Inventor _____

Residence _____ Signature _____

Post Office Address: _____

Citizenship _____